Semaglutide · source year
4 selected, source-linked Semaglutide records carrying a 2017 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
4 selected records.
2 represented types.
4 distinct public records.
Cited chronology
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 209637 with status AP dated 2017-12-05, and names semaglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02079870 at 2026-07-30T21:22:00.245Z. Its registry update date was 2017-12-02, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2017-21176, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02022254 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-04-04, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗